Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Primary Myelofibrosis 1Polycythemia Vera 1Lymphoma, Follicular 1

Interventions

ruxolitinib 13Cyclophosphamide 5Tacrolimus 4fludarabine phosphate 3Whole-Body Irradiation 3Stem Cell Transplantation 3Specimen Handling 3Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3Cyclosporine 3fludarabine 2fedratinib 2Sirolimus 2Injections 2Busulfan 2Biopsy 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2veliparib 1umbralisib 1thymoglobulin 1selinexor 1reparixin 1piperine 1pegylated granulocyte colony-stimulating factor 1navitoclax 1luspatercept 1letermovir 1itacitinib 1iadademstat 1demethoxycurcumin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Primary Myelofibrosis × umbralisib × 90 days × Clear all
NCT02493530 2026-05-19

TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

Vanderbilt-Ingram Cancer Center

Phase 1 Completed
60 enrolled
Myeloid

Polycythemia Vera, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡